HematologyNews.net

Hematology Xagena

Xagena Mappa
Medical Meeting
Cardiobase
Xagena Salute

Search results for "Ibrutinib"

Bruton's tyrosine kinase ( BTK ) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, Ibrutinib ( Imbruvica ), a BTK inhibitor, ...


Two clinical studies published in the New England Journal of Medicine ( NEJM ) suggest that the novel agent Ibrutinib shows real potential as a safe, effective, targeted treatment for adults with chro ...


The Food and Drug Administration ( FDA ) has expanded the approved use of Imbruvica ( Ibrutinib ) for chronic lymphocytic leukemia ( CLL ) patients who have received at least one previous therapy.Chro ...


Patients with chronic lymphoid leukemia ( CLL ) or small lymphocytic lymphoma ( SLL ) who experience short response duration or adverse cytogenetics have poor outcomes. Researchers have evaluated th ...


Chemoimmunotherapy has led to improved numbers of patients achieving disease response, and longer overall survival in young patients with chronic lymphocytic leukaemia; however, its application in eld ...


Results from a sub-analysis of the phase 2 RESONATE-17 study has shown Ibrutinib ( Imbruvica ) was associated with robust efficacy and a positive risk-benefit profile in patients with relapsed or refr ...


A clinical trial has shown that patients with a specific molecular subtype of diffuse large B-cell lymphoma ( DLBCL ) are more likely to respond to the drug Ibrutinib ( Imbruvica ) than patients with ...